Journal
NATURE IMMUNOLOGY
Volume 10, Issue 4, Pages 356-360Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.1701
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z99 AR999999] Funding Source: Medline
Ask authors/readers for more resources
Protein kinases, which serve critical functions in signaling pathways in all cells, are popular therapeutic targets. At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency. Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compounds target more than one kinase. Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities. In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available